Global Virtual Session Border Controller (SBC) Market Outlook 2023-2036

The global immunoassay market is set to grow at a CAGR of 7.29% over the forecast period, i.e., 2024-2036. This growth of the market is set to be dominated by growing product launch& approval, along with rising biotechnology & pharmaceutical sectors. Additionally, the market is also growing on account of the rising geriatric population, and growing cases of COVID-19. The market is set to gather a revenue of approximately USD 65 billion by the end of 2036, up from a revenue of over USD 25 billion in the year 2023.

The global market for immunoassay is segmented into numerous segment which include technology, product, specimen, application, and end user. By specimen the market is segmented into blood, saliva, urine, and others. Out of these segments, the blood segment is estimated to generate the highest revenue of over 36 billion by the end of 2036, up from as revenue of close to USD 13 billion in the year 2022. Growing use of blood specimens in a wide range of parameters, such as antigens.

On the basis of region, the global immunoassay market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is predicted to gather the largest market revenue of about USD 25 billion by the end of 2036, up from a revenue of over USD 10 billion in the year 2023.

Some of the prominent industry leaders in the global immunoassay market that are included in our report are Abbott, Beckman Coulter, Inc., QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Becton, Dickinson, and Company, BIOMÉRIEUX, F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Inc., Siemens Healthinners AG, Merck KGaA, Hologic, Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., MIZUHO MEDY Co., Ltd., Immunosens Co., Ltd., Immuno-Biological Laboratories Co, Ltd., H.U. Group Holdings, Inc., Sysmex Corporation, Sumitomo Bakelite Co., Ltd., and others.